CPL207280 (CPL 207280) is a novel potent, selective GPR40/FFA1 agonist with EC50 of 80 nM in a Ca2+ influx assay, shows greater potency than fasiglifam (EC50=270 nM).

AZ423 (AZ13595423, AZ-423) is a potent, selective G-protein-coupled receptor GPR120 (FFAR4) agonist with IC50 of 0.36/0.51 uM for huamn/mouse GPR120, respectively.

AZ13595491 (AZ491) is a potent, selective G-protein-coupled receptor GPR120 (FFAR4) agonist with IC50 of 0.74/1.0 uM for huamn/mouse GPR120, respectively.

2CTAP is a small molecule inverse agonist of FFA2 receptor signalling, inhibits constitutive Ca2+ levels, antagonised acetate-induced pERK1/2 and prevents damage following IRI, has no effect on cAMP.

ZINC621433144 is a Gi-biased, high-affinity full agonist of dopamine D4 receptor with Ki of 4.3 nM and cAMP EC50 of 0.18 nM.

R-VK4-40 is a highly selective, potent and orally available dopamine D3 receptor (D3R) antagonist with Ki of 6.8 nM, >1500-dold selectivity over D2R.

PG01037 is a potent selective dopamine D3 receptor antagonist with binding Ki of 0.7 nM, displays 133- and 540-fold selectivity over D2 and D4 receptors, respectively.

ML321, CAS 1596117-75-7, ML 321, D2R antagonist. ML321 is a selective small molecule dopamine D2 receptor (D2R) antagonist with binding Ki of 120 nM, exhibits an excellent D2 versus D1, D3, D4 and D5 receptor selectivity.

GR-103691 is a potent, selective dopamine D3 receptor antagonist with binding Ki of 0.4 nM, >100-fold selectivity over D1 and D4 receptors.

CJB 090 (CJB090) is a selective partial agonist of dopamine D3 receptor with binding Ki of 0.6 nM, CJB 090 is 97-fold selective for D3 receptors over D2.

CAB2-015 is a high affinity dopamine D3 receptor (D3R) antagonist/partial agonist withIC50 of 7.4 nM, Ki of 0.351 nM, 45-fold selectivity over D2R.

CAB-01-019 is potent, selective dopamine D4 receptor (D4R) full antagonist with binding Ki of 2.2 nM, >500-fold selectivity over D2R and D3R.

BAK4-54 is a high affinity dopamine D3 receptor (D3R) antagonist/partial agonist withIC50 of 8.0 nM as full D3R antagonist, EC50 of 140 nM as partial D3R agonist.

AG-0029 is a highly potent agonist of dopamine D2/D3 receptor (EC50=0.08 nM) and a moderate affinity antagonis of H3 receptor (IC50=111 nM).

(±)-ABS01-113 is a structural analog of the D3R partial agonist, (±)-VK4-40.

(S)-ABS01-113 is a potent, highly selective and efficacious dopamine D3 receptor (D3R) partial agonist with EC50 of 7.6 nM, binds with high affinity to D3R with Ki value of 0.84 nM, >1,000-fold selectivity over D2R.

(R)-ABS01-113 is a potent, selective dopamine D3 receptor (D3R) antagonist with IC50 of 11.4 nM, binds with high affinity to D3R with Ki value of 0.34 nM.

(±)VK4-40 is a highly selective and metabolically stable D3 partial agonist, shows high affinity for D3 receptor (Ki=0.35 nM) and high selectivity for D3 over the D2 receptor.

GSK598809 (GSK-598809) is a potent, selective dopamine D(3) receptor antagonist with Ki value of 6.2 nM, >100-fold selectivity over D2 receptor.

NBI-35965 is a potent, selective antagonist of corticotropin-releasing factor 1 (CRF1) receptor with Ki of 4 nM, >1000-fold selective over CRF2.

BMK-C205 (BMK-C 205) is a potent, selective corticotropin-releasing hormone receptor 1 (CRF1R) antagonist with IC50 of 74 nM in calcium mobilization assays, blocks hypothalamus-pituitary-adrenal (HPA) axis activation.

YM-355179 is a potent selective, and orally available antagonist of CC chemokine receptor 3 (CCR3) with binding IC50 of 7.6 nM (CCL5).

YM-344484 (YM344484) is a potent, selective dual antagonist of chemokine CCR3 receptor and histamine H1 receptor, potently inhibits both the CCL11-induced Ca2+ influx in human CCR3-expressing cells (Kb=1.8 nM) and histamine-induced Ca2+ influx in histamin

VUF15485 is a small-molecule agonist of the atypical chemokine receptor ACKR3 with binding pIC50 of 8.3, and pEC50 of 7.6 in BRET-based β-arrestin2 recruitment assay.

UCUF-965 (UCUF965) is a potent partial agonist and positive allosteric modulator of CXCR4 with EC50 of 0.02 uM, Emax=44% for CXCR4/CXCL12 signaling for β-arrestin-2 recruitment.

UCB35625 is a potent, selective inhibitor of CCR1 and CCR3, inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants with IC50 of 9.57 and 93.8 nM respectively.

SCH-479833 is a potent, specific and orally active CXCR1 and CXCR2 antagonist with Ki of 0.17 and 7 nM, respectively.

RAP-103 is an orally active, stabilized pentapeptide analog of DAPTA (D-ala-peptide T-amide), and multi-chemokine receptor antagonist.

NUCC-390 dihydrochloride (NUCC390) is a small molecule agonist of CXCR4, recapitulates the activity of CXCL12α.

LN6023 (LN-6023) a potent, selective and first-in-class inhibitor of the atypical chemokine receptor 3 (ACKR3, CXCR7) with β-arrestin EC50 of 3.5 uM.